Mustafa Basree, Radiation Oncologist at Cleveland Clinic, shared a post on X:
“Data from Ph3 RCT of TORPEdO trial looking at photon vs proton RT for patients with LA-OPSCC receiving chemoRT showed NO benefit in feeding-tube dependence, other HRQoL, LRC, and survival.
Fully optimized, high quality, IMRT OUTPERFORMS IMPT.
TORPeDO argues against earlier QoL benefit seen w/ MDACC study (Frank et al). Excellent discussant summarizing the two studies. More studies are underway.
“
